{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T04:22:57Z","timestamp":1741926177735,"version":"3.38.0"},"reference-count":9,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2024,12,14]],"date-time":"2024-12-14T00:00:00Z","timestamp":1734134400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,3,13]]},"DOI":"10.1093\/eurheartj\/ehae838","type":"journal-article","created":{"date-parts":[[2024,12,14]],"date-time":"2024-12-14T21:14:26Z","timestamp":1734210866000},"page":"1080-1081","source":"Crossref","is-referenced-by-count":0,"title":["Weekly Journal Scan: HELIOS-B sheds light on new therapeutic options for transthyretin amyloidosis with cardiomyopathy"],"prefix":"10.1093","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4218-3066","authenticated-orcid":false,"given":"Daniela","family":"Pedicino","sequence":"first","affiliation":[{"name":"Department of Cardiovascular Medicine, Fondazione Policlinico Universitario A. Gemelli\u2014IRCCS , Largo A. Gemelli 8, Rome 00168 ,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9642-8380","authenticated-orcid":false,"given":"Massimo","family":"Volpe","sequence":"additional","affiliation":[{"name":"Department of Clinical and Molecular Medicine, Sapienza University of Rome , Via di Grottarossa 1035, Rome ,","place":["Italy"]},{"name":"IRCCS San Raffaele Roma , Via di Valcannuta 250, Rome ,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2024,12,14]]},"reference":[{"key":"2025031314395772700_ehae838-B1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2409134","article-title":"Vutrisiran in patients with transthyretin amyloidosis with cardiomyopathy","author":"Fontana","year":"2024","journal-title":"N Engl J Med"},{"key":"2025031314395772700_ehae838-B2","doi-asserted-by":"publisher","first-page":"3517","DOI":"10.1093\/cvr\/cvac119","article-title":"Transthyretin cardiac amyloidosis","volume":"118","author":"Porcari","year":"2023","journal-title":"Cardiovasc Res"},{"key":"2025031314395772700_ehae838-B3","doi-asserted-by":"publisher","first-page":"2893","DOI":"10.1093\/eurheartj\/ehad347","article-title":"Conventional heart failure therapy in cardiac ATTR amyloidosis","volume":"44","author":"Ioannou","year":"2023","journal-title":"Eur Heart J"},{"key":"2025031314395772700_ehae838-B4","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"key":"2025031314395772700_ehae838-B5","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1161\/CIRCULATIONAHA.118.035831","article-title":"Effects of patisiran, an RNA interference therapeutic, on cardiac parameters in patients with hereditary transthyretin-mediated amyloidosis","volume":"139","author":"Solomon","year":"2019","journal-title":"Circulation"},{"key":"2025031314395772700_ehae838-B6","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1056\/NEJMoa2305434","article-title":"Efficacy and safety of acoramidis in transthyretin amyloid cardiomyopathy","volume":"390","author":"Gillmore","year":"2024","journal-title":"N Engl J Med"},{"key":"2025031314395772700_ehae838-B7","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1001\/jamacardio.2020.1738","article-title":"Initial experience prescribing commercial tafamidis, the most expensive cardiac medication in history","volume":"5","author":"Masri","year":"2020","journal-title":"JAMA Cardiol"},{"key":"2025031314395772700_ehae838-B8","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1161\/CIRCULATIONAHA.119.045093","article-title":"Cost-effectiveness of tafamidis therapy for transthyretin amyloid cardiomyopathy","volume":"141","author":"Kazi","year":"2020","journal-title":"Circulation"},{"key":"2025031314395772700_ehae838-B9","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.ejim.2024.01.001","article-title":"Breakthrough advances enhancing care in ATTR amyloid cardiomyopathy","volume":"123","author":"Porcari","year":"2024","journal-title":"Eur J Intern Med"}],"container-title":["European Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/46\/11\/1080\/61181039\/ehae838.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/46\/11\/1080\/61181039\/ehae838.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T14:40:07Z","timestamp":1741876807000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartj\/article\/46\/11\/1080\/7923988"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,14]]},"references-count":9,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2024,12,14]]},"published-print":{"date-parts":[[2025,3,13]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartj\/ehae838","relation":{},"ISSN":["0195-668X","1522-9645"],"issn-type":[{"type":"print","value":"0195-668X"},{"type":"electronic","value":"1522-9645"}],"subject":[],"published-other":{"date-parts":[[2025,3,14]]},"published":{"date-parts":[[2024,12,14]]}}}